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Accepted 29 October 2008AbstractObjective: Our purpose was to measure the agreement, reliability, construct validity, and feasibility of a measurement tool to assess
systematic reviews (AMSTAR).
Study Design and Setting: We randomly selected 30 systematic reviews from a database. Each was assessed by two reviewers using:
(1) the enhanced quality assessment questionnaire (Overview of Quality Assessment Questionnaire [OQAQ]); (2) Sacks’ instrument; and
(3) our newly developed measurement tool (AMSTAR). We report on reliability (interobserver kappas of the 11 AMSTAR items), intraclass
correlation coefficients (ICCs) of the sum scores, construct validity (ICCs of the sum scores of AMSTAR compared with those of other
instruments), and completion times.
Results: The interrater agreement of the individual items of AMSTAR was substantial with a mean kappa of 0.70 (95% confidence
interval [CI]: 0.57, 0.83) (range: 0.38e1.0). Kappas recorded for the other instruments were 0.63 (95% CI: 0.38, 0.78) for enhanced OQAQ
and 0.40 (95% CI: 0.29, 0.50) for the Sacks’ instrument. The ICC of the total score for AMSTAR was 0.84 (95% CI: 0.65, 0.92) compared
with 0.91 (95% CI: 0.82, 0.96) for OQAQ and 0.86 (95% CI: 0.71, 0.94) for the Sacks’ instrument. AMSTAR proved easy to apply, each
review taking about 15 minutes to complete.
Conclusions: AMSTAR has good agreement, reliability, construct validity, and feasibility. These findings need confirmation by a broader
range of assessors and a more diverse range of reviews.  2009 Elsevier Inc. All rights reserved.
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Systematic reviews have become the standard approach in
assessing and summarizing applied health research, but the
quality of systematic reviews has received relatively little at-
tention. Quality can be defined as the likelihood that the de-
sign of a systematic review will generate unbiased results [1].
Systematic reviews have appeared in medical journals
since the late 1970s. Thousands of systematic reviews are* Corresponding author: CIET Institute of Population Health, 1 Stew-
art Street, Room 319, Ottawa, Ontario, K1N 6N5, Canada. Tel.: þ613-562-
5800 ext. 8571; fax: þ613-562-5392.
E-mail address: bshea@ciet.org or bevshea@uottawa.ca (B.J. Shea).
0895-4356/09/$ e see front matter  2009 Elsevier Inc. All rights reserved.
doi: 10.1016/j.jclinepi.2008.10.009available on all areas of health care, and a substantial por-
tion of them has been produced by the Cochrane Collabo-
ration. High methodoliogical quality is a pre-requisite for
valid interpretation and application of review findings.
However, systematic reviews are complex exercises, and
assessing quality can be a daunting task. Clinicians and
policy makers require guidance, which is not provided
adequately by the available literature on the quality of sys-
tematic reviews. In a previous study, we summarized this
literature, tested quality assessment tools, and reached the
conclusion that current instruments for conducting method-
ological quality assessments of systematic reviews were
suboptimal and needed revision and updating [2]. No single
instrument has achieved dominance in terms of general use.
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 AMSTAR, a new instrument for evaluating system-
atic reviews, is reliable, valid, and easy to use.
 Currently, there is no agreement on which instru-
ment to use when measuring the quality of system-
atic reviews. AMSTAR, a development of existing
instruments, provides a possible solution.
 The instrument should be widely evaluated to con-
firm the performance metrics recorded here. The in-
strument should be updated as new knowledge is
generated regarding factors that affect the quality
of systematic reviews.
One popular instrument (QUality Of Reporting Of Meta-
analyses [QUORUM]) is a reporting checklist, not a meth-
odological quality assessment instrument.
Our review revealed a variety of weaknesses in the avail-
able instruments [2]. Our intention was not to come up with
a truly novel approach, but to bring clarity to the field by:
reviewing the available instruments, further developing
and updating existing instruments, and providing a model
that was validated and useable (in terms of comprehensibil-
ity and acceptable time for completion). Based on this eval-
uation, we created a measurement tool to assess systematic
reviews (AMSTAR). This refines and enhances work pre-
sented in previously published instruments (by Oxman
and Guyatt, 1991 [3] and Sacks et al., 1987 [4]) [5]. The
present study concerns the internal validation of AMSTAR
using the set of reviews used in its development. Here we
focus on parameters of agreement, reliability; construct val-
idity, and feasibility through comparisons with other instru-
ments. An external validation of AMSTAR has been
reported separately [6].2. Methods
We used a computer-generated random sample of 30
(20%) of 151 systematic reviews that were used in the
development of the instrument [5]. This sample contained
11 Cochrane and 19 non-Cochrane reviews, including
meta-analyses and qualitative reviews. The topics of the
reviews ranged across the spectrum of medicine [7e36].
Two reviewers (one without formal training) applied the
new AMSTAR instrument and the two quality assessment
tools, the enhanced Overview of Quality Assessment
Questionnaire (OQAQ, originally developed by Oxman
and Guyatt), and the instrument developed by Sacks
et al. to all 30 reviews (C.H., B.J.S.) [3,4]. For each re-
viewer, the data set extracted contained three quality rat-
ings for each review, yielding a total of six ratings per
review.2.1. Agreement and reliability
We calculated overall agreement and Cohen’s kappa for
each item (‘‘yes’’ scores vs. any other scores) [37]. Bland
and Altman’s limits of agreement method explained the
agreement graphically [38e40]. We awarded each item
scoring ‘‘yes’’ one point and summed these to calculate a to-
tal score. Intraclass correlation coefficients (ICCs) assessed
the reliability of this total score [41]. We further scrutinized
items and reviews with kappa values below 0.50. Finally,
we repeated the exercise for the OQAQ and Sacks’ instru-
ments. Kappa values of less than 0 were rated as less than
chance agreement; 0.01e0.20, slight agreement;
0.21e0.40, fair agreement; 0.41e0.60, moderate agree-
ment; 0.61e0.80, substantial agreement; and 0.81e0.99,
almost perfect agreement. [42]
2.2. Construct validity
The new instrument already has high face and content val-
idity by virtue of its construction process [5]. In the current
study, we assessed construct validity by converting the mean
total score (mean of two raters C.H. and B.J.S.) of each of the
30 reviews to a percentage of the maximum score for each of
the three instruments. ICCs then assessed convergence of the
total scores between each pair of instruments (AMSTARe
OQAQ, AMSTAReSacks, and OQAQeSacks).
2.3. Feasibility
Based on a guideline for assessing feasibility of instru-
ment use developed by the Outcome Measures in Rheuma-
tology (OMERACT) group [43], we compared the
feasibility of the new instrument with that of the existing
instruments by recording the time it took to complete scor-
ing and the instances where scoring was difficult or impos-
sible. The wording of individual items is critical for the
performance of AMSTAR and fine-tuning is expected to
be an ongoing task.
SPSS (version 13; SPSS Inc., Chicago, IL, USA) and
MedCalc Software (Mariakerke, Belgium) were used to an-
alyze the data, and the results were expressed as means and
95% confidence intervals (CIs) unless otherwise noted.3. Results
The sample of 30 reviews adequately covered a wide
range of quality, albeit with some underrepresentation of
poor-quality reviews. Overall quality scores on AMSTAR
ranged from 3 to 10 (out of a maximum of 11) with a flat
distribution between 3.5 and 10 and a mean percentage
score of 49.4%. The overall quality scores on Sacks’ instru-
ment ranged from 5 to 16 (out of a maximum score of 24),
with a mean percentage score of 41.6%, and for OQAQ,
scores ranged from 3 to 10 (out of a maximum score of
10), with a mean percentage score of 63.3%.
Fig. 1. Bland and Altman plot of interrater agreement on a measurement
tool to assess systematic reviews’ total score.
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The interobserver agreement of the individual items in
the AMSTAR was high: mean 5 0.88 (range: 0.73e1.0)
with a mean kappa of 0.70 (95% CI: 0.57, 0.83) (range:
0.38e1.0). However, items 4 (publication status), 7 (report
of assessment of scientific quality), and 9 (appropriate
method to combine studies) scored fair to moderate at
0.38, 0.42, and 0.45, respectively. On the first two of these
items, overall agreement was substantial at 0.80 and the
relatively low kappa may be explained by a skewed distri-
bution, that is, a high number of reviews in which the
reviewers agreed on the score ‘‘no’’ (item 4) and ‘‘yes’’
(item 7), respectively. On item 8, overall agreement was
also satisfactory at 0.74. Compared with the other instru-
ments, agreement on individual items was similar to
OQAQ: mean kappa of 0.63 (95% CI: 0.39, 0.78) (range
0.39e0.84), and superior to the Sacks’ instrument: mean
kappa of 0.40 (95% CI: 0.29, 0.50) (range: 0.47 to
0.93). In these instruments, fair to moderate agreement
was also seen in the items covering assessment of scientific
validity, statistical combinability, and comprehensive liter-
ature searching (Table 1).
For the AMSTAR total score, the mean difference
between the two observers’ scores was 0.2 (0.36e0.91).
Agreement was similar in reviews with high- and low-qual-
ity scores (Fig. 1).
The interobserver ICC for the total score was excellent
for all instruments: AMSTAR, 0.84 (95% CI: 0.65, 0.92);
OQAQ, 0.91 (95% CI: 0.82, 0.96); and Sacks’ instrument,
0.86 (95% CI: 0.71, 0.94). In one non-Cochrane review
[12], observers differed by 3 points (6 vs. 9). In this review,
the differences were noted on AMSTAR questionsTable 1
Assessment of the interrater agreement for AMSTAR
Items Kappa (95% CI)
1. Was an ‘‘a priori’’ design provided? 0.80 (0.63, 0.90)
2. Was there duplicate study selection and data
extraction?
0.80 (0.17, 0.81)
3. Was a comprehensive literature search
performed?
0.72 (0.40, 0.87)
4. Was the status of publication (i.e., grey
literature) used as an inclusion criterion?
0.38 (0.28, 0.70)
5. Was a list of studies (included and excluded)
provided?
0.56 (0.07, 0.79)
6. Were the characteristics of the included studies
provided?
0.74 (0.45, 0.86)
7. Was the scientific quality of the included studies
assessed and documented?
0.42 (0.23, 0.72)
8. Was the scientific quality of the included studies
used appropriately in formulating conclusions?
0.74 (0.45, 0.87)
9. Were the methods used to combine the findings
of studies appropriate?
0.45 (0.12, 0.70)
10. Was the likelihood of publication bias assessed? 0.88 (0.75, 0.94)
11. Were potential conflicts of interest included? 0.92 (0.83, 0.96)
Abbreviations: AMSTAR, a measurement tool to assess systematic
reviews; CI, confidence interval.addressing duplication study selection and data extraction
(item 2), publication status (item 4), and methods used to
combine studies (item 9). In one Cochrane review [15], ob-
servers differed by 4 points (1 vs. 5). In this review, differ-
ences were noted on AMSTAR questions assessing the
a priori design (item 1), publication status (item 4), scien-
tific quality (item 7), and methods used to combine studies
(item 9). The overall quality of Cochrane reviews included
in this data set was somewhat higher than non-Cochrane
reviews.
The qualitative analysis of the data on agreement led us
to make minor modifications to the wording of some items.
In particular, under the original item regarding publication
bias, the wording was changed to clarify the purpose of the
question, that is, to ask whether the status of publication
was used as an inclusion criterion (see item 4 and footnote
in Appendix). Additional available electronic databases
were also added to the question on literature searching
(item 3) and I2 was added to the item on methods used to
combine findings (item 9).
3.2. Construct validity
Expressed as a percentage of the maximum score, the
results of AMSTAR showed convergence with the results
of the other instruments. ICC for AMSTAR was 0.66
(95% CI: 0.28, 0.84) against OQAQ and 0.83 (95% CI:
0.64, 0.92) against Sacks’ instrument. The ICC obtained
when comparing OQAQ with Sacks’ instrument was 0.86
(95% CI: 0.70, 0.93).
3.3. Feasibility
AMSTAR proved easy to apply, each review taking 14.9
(95% CI: 17.0, 12.8) minutes to complete. OQAQ took, on
average, 20.3 (95% CI: 22.5, 18.0) minutes to complete,
and Sacks’ instrument 34.4 (95% CI: 37.3, 31.6) minutes
(P ! 0.0001 for comparison between the three instru-
ments). Two of the reviewers expressed difficulty with
1016 B.J. Shea et al. / Journal of Clinical Epidemiology 62 (2009) 1013e1020scoring item 4 on publication status: ‘‘was the status of
publication (i.e., grey literature) used as an inclusion
criterion?’’4. Discussion
There has been a continued proliferation of (largely
unvalidated) scales and checklists for assessing the quality
of systematic reviews [44]. This causes confusion for those
who use reviews in making clinical and policy decisions
and who need to be able to distinguish good- from poor-quality
reviews. There is a need for a reliable and valid quality as-
sessment instrument that is easy to use. AMSTAR was devel-
oped to meet this need. Our aim was not to devise a truly
original instrument, but to develop and update the best avail-
able from the published literature. Our scan indicated that the
OQAQ developed by Oxman and Guyatt [3] and the rating
scale of Sacks et al. [4] were among the best out of more than
two dozen instruments assessed by us. We found that both in-
struments had been rigorously developed, but were dated in
some respects. We decided to improve the descriptors of
the items resulting in the ‘‘enhanced OQAQ’’ that we have
applied in the subsequent studies [2]. The checklist devel-
oped by Sacks et al. showed good quality and was especially
comprehensive but unwieldy in general use [4]. We based
AMSTAR on a development of both of these instruments.
Full details of this development process are published else-
where [5].
This study suggests that AMSTAR has good agreement,
reliability, construct validity, and feasibility to assess the
quality of systematic reviews. Its performance in terms of
agreement and reliability was similar to OQAQ and better
than Sacks’ instrument; it adds important items that are
not present in either instrument (e.g., publication status,
conflict of interest), and has better feasibility than OQAQ
or Sacks’ instrument. We think AMSTAR can be applied
to a wide variety of systematic reviews, but recognize that
it has only been tested on systematic reviews of randomized
control trials evaluating treatment interventions. We accept
that the relatively high reliability of total scores for
AMSTAR and OQAQ may be partly because of the raters’
familiarity with both instruments, and this reliability needs
to be tested more widely in the field.
AMSTAR showed good (convergent) construct validity
in comparison with the two existing instruments. A recently
published study concluded that the underlying construction
of OQAQ is designed for the assessment of meta-analyses.
Thus, it is difficult for any other type of review to score
highly on the OQAQ, and if the review does not have
a meta-analysis component, it may be deemed to have ma-
jor flaws [45]. AMSTAR can be scored both individually
(components) and as a checklist by summing the item
scores (overall score). It was psychometrically developed
to score each item as if it was not related to the others. Each
component came out separate in the factor analysis.Therefore, all reviews have equal chance of scoring well,
but meta-analysis will score slightly higher in the overall
results.
The feasibility of AMSTAR is documented in terms of
the time required to complete an assessment while using
it: about 10e15 minutes, which is substantially less than
the time needed to complete the other instruments.
In this study, we did not assess the external validity of
AMSTAR. This has been carried out separately and the
results have recently been published. In that analysis, we
looked at differences in overall scores and compared them
with the global assessments made by an informed panel.
We found very good correlations on the total scores [6].
There has been considerable discussion regarding the
merits of using individual component scores or summary
scores when assessing systematic reviews and individual
studies [45,46]. From a methodological standpoint, it is
worth assessing the component scores as they measure dif-
ferent elements, and some may be more important than
others in particular situations. Hence, a summary score
may obscure important strengths or weaknesses. In the case
of AMSTAR, we have tried to develop an instrument that is
pragmatic and of value to decision makers. It is valid and
easy to use and the total score is meaningful. By this, we
mean that we have ensured that the components are non-
overlapping and have separately validated the total score
against an external standard [5,6]. Hence, we believe that
decision makers can have some confidence that the compo-
nent scores measure different domains of quality and the
overall score is meaningful.
We feel that the main advantage of AMSTAR over the
OQAQ and Sacks’ instruments lies in its better compromise
between comprehensiveness and feasibility. It adds relevant
dimensions to those covered in the OQAQ without becoming
unwieldy, as with the Sacks’ instrument. For example, the
item ‘‘sources of support’’ was included in the original data
set and came out as a component in the factor analysis. Some
may doubt the usefulness of the item concerning conflict of
interest. We put a lot of thought into the name and description
of this item, using all available empirical evidence. In addi-
tion to the research previously discussed on this topic, more
recent studies also suggest that funding source influences
outcomes and quality of research [47]. In a study by Bion-
di-Zoccai [48], the authors concluded that reviewers who re-
ported previous not-for-profit funding were more likely to
carry out higher-quality systematic review. We believe that
funding sources are associated with bias in systematic re-
views and it is important to rate this aspect of their conduct.
The inclusion of unpublished studies is rated by AMSTAR.
This remains a controversial topic in systematic reviews. Sev-
eral examples in the drugs’ field have demonstrated the cru-
cial importance of including nonpublished data. In the case
of two Cox-2 inhibitors, rofecoxib and celecoxib, the incom-
plete reporting of vascular deaths and gastrointestinal events
skewed the results of trials that were used as the basis of im-
portant decisions [49]. More recently, several systematic
1017B.J. Shea et al. / Journal of Clinical Epidemiology 62 (2009) 1013e1020reviews/meta-analyses of antidepressant drugs have shown
that the inclusion of unpublished data dramatically alters
the perception of benefit in a negative way [50,51]. Based
on these examples, we felt it important to include an item in
AMSTAR dealing with unpublished studies.
During the development of AMSTAR, careful consider-
ation was given to the wording of the individual items and
minor adjustments were made where necessary; despite this
process, agreement between observers was disappointingly
low on three items. One of these items assessed publication
restriction. After discussion between observers, we re-
worded the descriptor slightly and this has improved agree-
ment. The reworded version is provided in Appendix. The
other two items describe ‘‘report of assessment of scientific
quality’’ and ‘‘appropriate method to combine studies.’’
Agreement was low on similar items in the other instru-
ments assessed here. Subjective judgment comes into play
when one is asked to assess whether quality of included
studies was assessed adequately. Conceivably, one could in-
crease reliability of assessment by providing more detailed
instructions or by adding more items or criteria. This
would, however, decrease feasibility. It should also be
noted that overall agreement on these items was good;
hence, their relatively low kappa values are likely causedTable 2
Characteristics of included studies
Author Year Journal type
1. Anonymous 1989 NEJM
2. Appel 1993 Arch Intern Med
3. Buring 1988 Rev Inf Dis
4. Chalmers 1977 NEJM
5. Clagett 1988 Ann Surg
6. Counsell 1996 Cochrane
7. Daya 1996 Cochrane
8. Duley 1996 Cochrane
9. Fanning 1992 Obstet Gynecol
10. Gent 1986 Chest
11. Gotzsche 1995 BMJ
12. Graves 1996 Cochrane
13. Henderson 1989 Ann Intern Med
14. Hodnett 1996 Cochrane
15. Hofmeyr 1996 Cochrane
16. Hopfenmuller 1994 Arzneim-Forsch
17. Hughes 1992 Fertil Steril
18. Kaufmann 1988 Health Psychol
19. Kramer 1996 Cochrane
20. Lycka 1990 Int J Dermatol
21. McGrath 1996 Cochrane
22. Mulrow 1988 JAMA
23. Ohlsson 1989 Am J Obstet Gynec
24. Perez-Escamilla 1994 Am J Public Health
25. Renfrew 1996 Cochrane
26. Renfrew 1996 Cochrane
27. Soares 1996 Cochrane
28. Thacker 1985 BJOG
29. Velanovich 1989 Surgery
30. Wilson 1992 J Hosp Infect
FSH, follicle stimulating hormone; hMG, human menopausal gonadotrophinby skewness in the responses, that is, most of the responses
in either the ‘‘yes’’ or the ‘‘no’’ category. This is a well-
known limitation of the kappa statistic [52].
Our study has other limitations. We did not compare AM-
STAR with the current state-of-the-art reporting quality
of meta-analysis (QUOROM) [53]. The reason for this is
that QUOROM is not specifically designed to assess method-
ological quality. Rather, it is specifically focused on the quality
of reporting (not conduct) of the review. This does not detract
from the utility of QUOROM, but its limited focus made it un-
suitable for our study. A further limitation of the present study
is the fact that the sample of reviews used is derived from the
original source used to develop AMSTAR (Table 2), and one
of the assessors is the principal investigator. Thus, application
to other reviews and by other assessors is necessary to discover
the full potential of this tool. Finally, the number of reviews
used to validate AMSTAR was rather small.
Our new instrument builds on previous work. Methodolo-
gists continue to struggle with methodological quality issues,
whereas decision makers struggle with the challenge of bas-
ing policy, clinical, or resource planning decisions on the
available evidence. The personal feedback received on AM-
STAR has been supportive. AMSTAR is now being used by























ol Preterm premature rupture of the membranes
Breastfeeding
Infant discharge times
Breastfeeding and early contact




; IVF, in vitro fertilization; GABA, gamma-aminobutyric acid.
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tive Practice and Organization of Care Group (EPOC) [54].
With publication of data on reliability and validity in
a peer-reviewed journal, we hope that it will help many re-
viewers with their task of assessing the methodological qual-
ity and incorporating the results into their systematic reviews.
In summary, AMSTAR is an empirically developed
instrument for documenting the quality of systematic re-
views. It was found to have good agreement, reliability,
and construct validity in a limited test setting. It combines
in one instrument a level of comprehensiveness and feasi-
bility not found in existing instruments. We encourage
others to test our new instrument on other samples of sys-
tematic reviews. Its ongoing application in the assessment
of the quality of systematic reviews will provide further
confirmation of its utility.
Further validation is needed to replicate the initial prom-
ising results, and this should involve a broader range of
assessors and a broader range of reviews to assess whether
the reliability and validity are confirmed in diverse circum-
stances.
Appendix: A measurement tool to assess systematic
reviews (AMSTAR)1. Was an ‘‘a priori’’ design provided?
The research question and inclusion criteria




, Not applicable2. Was there duplicate study selection and data
extraction?
There should be at least two independent data
extractors and a consensus procedure for dis-
agreements should be in place., Yes
, No
, Can’t answer
, Not applicable3. Was a comprehensive literature search
performed?
At least two electronic sources should be
searched. The report must include years and
databases used (e.g., Central, EMBASE, and
MEDLINE). Key words and/or MESH terms
must be stated, and where feasible, the search
strategy should be provided. All searches
should be supplemented by consulting current
contents, reviews, textbooks, specialized reg-
isters, or experts in the particular field of




, Not applicable4. Was the status of publication (i.e., grey liter-
ature) used as an inclusion criterion?
The authors should state that they searched
for reports regardless of their publication
type. The authors should state whether or not
they excluded any reports (from the system-




, Not applicable5. Was a list of studies (included and excluded)
provided?




, Not applicable6. Were the characteristics of the included
studies provided?
In an aggregated form, such as a table, data
from the original studies should be provided
on the participants, interventions, and out-
comes. The ranges of characteristics in all the
studies analyzed, e.g., age, race, sex, relevant
socioeconomic data, disease status, duration,
severity, or other diseases should be reported., Yes
, No
, Can’t answer
, Not applicable7. Was the scientific quality of the included
studies assessed and documented?
‘‘A priori’’ methods of assessment should be
provided (e.g., for effectiveness studies if the
author(s) chose to include only randomized,
double-blind, placebo-controlled studies, or
allocation concealment as inclusion criteria);
for other types of studies, alternative items
will be relevant., Yes
, No
, Can’t answer
, Not applicable8. Was the scientific quality of the included
studies used appropriately in formulating
conclusions?
The results of the methodological rigor and
scientific quality should be considered in the
analysis and the conclusions of the review,




, Not applicable9. Were the methods used to combine the find-
ings of studies appropriate?
For the pooled results, a test should be done to
ensure the studies were combinable, to assess
their homogeneity (i.e., Chi-squared test for
homogeneity, I2). If heterogeneity exists,
a random effects model should be used and/or
the clinical appropriateness of combining
should be taken into consideration (i.e., is it
sensible to combine?)., Yes
, No
, Can’t answer
, Not applicable10. Was the likelihood of publication bias
assessed?
An assessment of publication bias should in-
clude a combination of graphical aids (e.g.,
funnel plot, other available tests) and/or sta-
tistical tests (e.g., Egger regression test)., Yes
, No
, Can’t answer
, Not applicable11. Was the conflict of interest included?
Potential sources of support should be clearly
acknowledged in both the systematic review
and the included studies., Yes
, No
, Can’t answer
, Not applicable‘‘Can’t answer’’ is chosen when the item is relevant but not described
by the authors; ‘‘not applicable’’ is used when the item is not relevant, such
as when a meta-analysis has not been possible or was not attempted by the
authors.
a The original wording for question #4: Was the status of publication
(i.e., grey literature) used/not used as an exclusion criterion? The authors
should state that they searched for reports regardless of their publication
type. The authors should state whether or not they excluded any reports
(from the systematic review), based on their publication status, language etc.
References
[1] Moher D, Jadad AR, Nichol G, Penman M, Tugwell P, Walsh S. Assess-
ing the quality of randomized controlled trials: an annotated bibliogra-
phy of scales and checklists. Control Clin Trials 1995;16:62e73.
[2] Shea B, Dube C, Moher D. Assessing the quality of reports of system-
atic reviews: the QUOROM statement compared to other tools. In:
1019B.J. Shea et al. / Journal of Clinical Epidemiology 62 (2009) 1013e1020Egger M, Smith GD, Altman DG, editors. Systematic reviews in health
care: meta-analysis in context. London: BMJ Books; 2001. p. 122e39.
[3] Oxman AD, Guyatt GH. Validation of an index of the quality of re-
view articles. J Clin Epidemiol 1991;44:1271e8.
[4] Sacks H, Berrier J, Reitman D, Ancona-Berk VA, Chalmers TC. Meta--
analyses of randomized controlled trials. N Engl J Med 1987;316:450e5.
[5] Shea B, Grimshaw J, Wells G, Boers M, Andersson N, Hamel C,
et al. Development of AMSTAR: a measurement tool to assess the
methodological quality of systematic reviews. BMC Med Res Meth-
odol 2007;7:10.
[6] Shea BJ, Bouter LM, Peterson J, Boers M, Andersson N, Ortiz Z,
et al. External validation of a measurement tool to assess systematic
reviews (AMSTAR). PLoS ONE 2007;2(12):e135010.1371/journal.-
pone.0001350. Published online December 26, 2007.
[7] Anonymous. Effects of adjuvant tamoxifen and of cytotoxic therapy
on mortality in early breast cancer. An overview of 61 randomized
trials among 28,896 women. Early Breast Cancer Trialists’ Collabo-
rative Group. NEJM 1989;319:1681e92.
[8] Appel LJ, Miller ER, Seidler AJ, Whelton PK. Does supplementation
of diet with ‘‘fish oil’’ reduce blood pressure. Arch Intern Med
1993;153:1429e38.
[9] Buring JE, Evans DA, Mayrent SL, Rosner B, Colton T,
Hennekens CH. Randomized trials of aminoglycoside antibiotics:
quantitative overview. Rev Inf Dis 1988;10:951e7.
[10] Chalmers TC, Matta RJ, Smith H, Kunzler AM. Evidence favouring
the use of anticoagulants in the hospital phase of acute myocardial
infarction. NEJM 1977;297:1091e6.
[11] Clagett GP, Reisch JS.Prevention of venous thromboembolism ingeneral
surgical patients. Results of meta-analysis. Ann Surg 1988;208:227e40.
[12] Counsell C, Warlow C, Naylor R. Different patches in carotoid sur-
gery. Cochrane Library 1996 (issue 3).
[13] Daya S. Comparison of FSH and HMG in IVF. Cochrane Library 1996;(3).
[14] Duley L, Gulmezoglu AM, Henderson-Smart DJ. Anticonvulsants for
pre-eclampsia. Cochrane Library 1996;(3).
[15] Fanning J, Bennett TZ, Hilgers RD. Meta-analysis of cisplatin, doxoru-
bicin, and cyclophosphamide versus cisplatin and cyclophosphamide
chemotherapy of ovarian carcinoma. Obstet Gynecol 1992;80:954e60.
[16] Gent M, Roberts RS. A meta-analysis of the studies of dihydroergot-
amine plus heparin in the prophylaxis of deep vein thrombosis. Chest
1986;89:396Se400S.
[17] Gotzsche PC, Gjorup I, Bonnen H, Brahe NE, Becker U, Burcharth F.
Somatostatin vs placebo in bleeding oesophageal varices: randomised
trial and meta-analysis. BMJ 1995;310:1495e8.
[18] Graves P. Malaria vaccines. Cochrane Library 1996;(Issue 3).
[19] Henderson WG, Goldman S, Copeland J, Moritz TE, Harker LA. Anti-
platelet or anticoagulant therapy, after coronary artery bypass surgery:
a meta-analysis of clinical trials. Ann Intern Med 1989;111:743e50.
[20] Hodnett ED. Alternative versus conventional delivery settings.
Cochrane Library 1996;(3).
[21] Hofmeyr GJ. Abdominal decompression. Cochrane Library 1996;(3).
[22] Hopfenmuller W. Nackweis der therapeutischen Wirksamkeit eines
Ginkgo biloba-Spezial extrakes: Meta-Analyse von 11 klinischen
Studien bei Patienten mit Hirnleistungsstorungen im Alter.
Arzneimittel-Forschung 1994;44:1005e13.
[23] Hughes E, Fedorkow DM, Daya S, Sagle MA, van de Kopple P,
Collins JA. The routine use of gonadotropin-releasing hormone agonists
prior to invitro fertilization and gamete intra-fallopian transfer: a meta--
analysis of randomized controlled trials. Fertil Steril 1992;58:888e96.
[24] Kaufmann PG, Jacob RG, Ewart CK, Chesney MA, Muenz LR,
Doub N, et al. Hypertension Intervention Pooling Project. Health
Psychol 1988;7(Suppl):209e24.
[25] Kramer MS. Maternal antigen avoidance as lactation. Cochrane
Library 1996;(3).
[26] Lycka BA. Postherpetic neuralgia and systemic corticosteroid
therapy. Efficacy and safety. Int J Dermatol 1990;29:523e7.
[27] McGrath JJ, Soares KVS. Tardive dyskinesia and benzodiazepines.
Cochrane Library 1996;(3).[28] Mulrow CD, Mulrow JP, Linn WD, Aguilar C, Ramirez C. Relative
efficacy of vasodilator therapy in chronic congestive heart failure.
Implications of randomized trials. JAMA 1988;259:3422e6.
[29] Ohlsson A. Treatments of preterm premature rupture of the
membranes: a meta-analysis. Am J Obstet Gynecol 1989;160:
890e906.
[30] Perez-Escamilla R, Pollitt E, Lonnerdal B, Dewey KG. Infant feeding
policies in maternity wards and their effect on breast-feeding success:
an analytical overview. Am J Public Health 1994;84:89e97.
[31] Renfrew MJ, Lang S. Breastfeeding and discharge times. Cochrane
Library 1996;(3).
[32] Renfrew MJ, Lang S. Breastfeeding and early contact. Cochrane
Library 1996;(3).
[33] Soares KVS, McGrath JJ, Deeks JJ. Tardive dyskinesia and GABA
agonist drugs. Cochrane Library 1996;(3).
[34] Thacker SB. Quality of controlled clinical trials. The case of imaging
ultrasound in obstetrics: a review. BJOG 1985;92:437e44.
[35] Velanovich V. Crystalloid versus colloid fluid resuscitation: a meta-
analysis of mortality. Surgery 1989;105:65e71.
[36] Wilson APR, Shrimpton S, Jaderberg M. A meta-analysis of the use
of amoxycillin-clavulanic acid in surgical prophylaxis. J Hosp Infect
1992;22:9e21.
[37] Cohen J. A coefficient of agreement for nominal scales. Educ Psychol
Meas 1960;20:37e46.
[38] Bland JM, Altman DG. Statistical methods for assessing agreement
between two methods of clinical measurement. Lancet 1986;i:
307e10.http://www-users.york.ac.uk/|mb55/meas/ba.htm.
[39] Bland JM, Altman DG. Statistical methods for assessing agreement
between measurements. Biochim Clin 1987;11:399e404.
[40] Anonymous. This week’s citation classic: comparing methods of clinical
measurement. Curr Contents 1992; CC/NUMBER 40: 8. Available at
http://garfield.library.upenn.edu/classics1992/A1992JN24800001.pdf.
[41] Uebersax JS. Diversity of decision-making models and the measure-
ment of inter-rater agreement. Psychol Bull 1987;101:140e6.
[42] Cohen J. Weighted kappa: nominal scale agreement with provision
for scaled disagreement or partial credit. Psychol Bull 1968;70:
213e20.
[43] Tugwell P, Bombardier C. A methodological framework for developing
and selecting endpoints in clinical trials. J Rheumatol 1982;9:758e62.
[44] Singh S, Bai A, Lal A, Yu C, Ahmed F. Developing evidence-based
best practices for the prescribing and use of proton pump inhibitors in
Canada. Ottawa, Canada: The Canadian Agency for Drugs and Tech-
nologies in Health (CADTH); 2006.
[45] Balk E, Bonis P, Moskowitz H, Schmid C, Ioannidis J, Wang C, et al. Cor-
relation of quality measures with estimates of treatment effect in meta-
analyses of randomized controlled trials. JAMA 2002;287:2973e82.
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